AteloGene™ Local or Systemic Use

This product is a kit for delivering siRNA into animal tissues by local or systemic administration in mice and then efficiently introducing it into the cells.

AteloGene™ Flyer 

Characteristics of Atelocollagen FAQ
Atelocollagen is a collagen solubilized by protease, but its physical properties are virtually identical to those of natural, unsolubilized collagen. Furthermore, atelocollagen additionally has superior characteristics;----- More

Animation for understanding AteloGene™
RNA interference (RNAi) is a mechanism in which fragments of double-strand ribonucleic acid (dsRNA) interfere with the expression of a specific gene whose sequence is complementary to the dsRNA. Recently, RNAi medicines, that inhibit the expression of genes responsible for diseases, have been studied actively. However, the delivery of siRNA in vivo had become a big issue because siRNA is unstable in vivo.

KOKEN(Tokyo) developed a new siRNA delivery system, “AteloGene™”. This system is mediated by atelocollagen that is a solubilized collagen obtained by protease treatment, and transfects siRNA in vivo efficiently and safety with each local administration and systemic administration.

Mechanism of RNAi and AteloGene™

<Industrial property rights>
Concerning the technique of introducing the nucleic acid component using this kit and collagen, Dainippon Sumitomo Pharma Co., Ltd. and KOKEN Co., Ltd. has either obtained the patent or the patent is under application (PCT/JP02/06137) in Japan and various countries abroad. The usage of this product is limited to application (PCT/JP02/06137) in Japan and various countries abroad. The usage of this product is limited to tests and researches. Other usage of this product may infringe the patent. Please pay attention in this regard.

When mixed with synthetic siRNA at an appropriate concentration and ratio, atelocollagen, which is a major component of “AteloGene™” forms a complex appropriate for administration into the body. siRNA that is prepared into a complex with atelocollagen is efficiently delivered in vivo and introduced into the cells.

> Immediate administration to experimental animals by simple mixing the synthetic siRNA with “AteloGene™”.
> Efficient in vivo transfection of siRNA.
> The effect of RNAi of preventing degradation by RNase persists for a long time.
>“AteloGene™” has no toxicity, and its main component is atelocollagen that demonstrates high biological compatibility.
> It is possible to choose “AteloGene™ Local Use” for local administration or “AteloGene™ Systemic Use” for systemic administration by injection to the tail vein
> Since “AteloGene™ Local Use” for local administration is gelated in the body, siRNA is securely kept at the administration site
> Since “AteloGene™ Systemic Use ” for systemic administration is not gelated in the body but circulated in the blood after injection into the tail vein, siRNA is efficiently delivered to the whole body

Mechanism of siRNA transfection using “ AteloGene™” Mechanism

This kit is intended for 10 times of administration.

Contents of kit

Procedures

AteloGene™ Manual

<References>
1. Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. Kinouchi N, Ohsawa Y, Ishimaru N, et al. Gene Ther. 2008 Aug;15(15):1126-30
2. Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity. Ishimoto T, Takei Y, Yuzawa Y, et al. Mol Ther. 2008 Feb;16(2):387-95
3. RPN2 gene confers docetaxel resistance in breast cancer. Honma K, Iwao-Koizumi K, Takeshita F, et al. Nat Med. 2008 Sep;14(9):939-48
4. An siRNA against JC virus (JCV) agnoprotein inhibits JCV infection in JCV-producing cells inoculated in nude mice. Matoba T, Orba Y, Suzuki T, et al. Neuropathology. 2008 Jun;28(3):286-94
5. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Tazawa H, Tsuchiya N, Izumiya M, et al. Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15472-7.
6. Characterization of the Recurrent 8p 11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer. Bernard-Pierrot I, Gruel N, Stransky N, et al. Cancer Res. 2008 Sep 1;68(17):7165-75

<NOTE>
# Storage
Storage temperature : 2-10°C(do not freeze)
Effective period: 5 years from the manufacturing date indicated on the box
Precautions for storage
  - Gelation and thermal denature occur in “AteloGene™” at a temperature higher than 20°C. Never use “AteloGene™” that was once gelated or thermally denatured.
  - Freezing “AteloGene™” causes bubbles in the mixture and the dispersion of components.  Never use “AteloGene™” that was once frozen.

# Precautions for use
1) This product is a reagent for research use only.Its application to the human body is strictly prohibited.Do not use it for any purposes other than for research purposes.
2) Be sure to read the instruction manual before use. The manufacturer is not liable for the results of usage by methods other than that described in the instruction manual. Depending on the type of siRNA, administration target or administration method, the expected effect may not always be obtained.